TGFB1 and cancer: Also, affected by the activity of antagonist molecular pathways, induced by surrounding elements in the TME and other cancer cells, the dynamics of TGF-β signaling might change from normal to malignant cells (and even from early to late-stage cancer cells) thereby influencing how different patients (or different cells in the same patient) respond to the therapy.